Bridgepoint Group plc ("Bridgepoint" or the "Company")

Admission of New Ordinary Shares and Total Voting Rights

Further to Bridgepoint's announcement on 26 September 2024 in connection with the proposed issue of 3,324,889 ordinary shares of £0.00005 each ("**New Ordinary Shares**") the Company announces that the New Ordinary Shares have today been admitted to the Official List and to trading on the LSE's main market for listed securities.

In conformity with the Financial Conduct Authority's Disclosure and Transparency Rules, Bridgepoint announces that its total issued share capital following the issue of the New Ordinary Shares comprises:

- 822,641,949 ordinary shares of £0.00005 each with voting rights; and
- 500 deferred shares of £81 each, 1 deferred share of £1, and 1 deferred share of £0.01, each with no voting rights.

Bridgepoint holds no shares in treasury.

The total number of voting rights in the Company is therefore 822,641,949, and this figure may be used by shareholders at such time as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Bridgepoint under the Disclosure Guidance and Transparency Rules.

Capitalised terms not otherwise defined in this announcement have the meanings given to them in the circular published on 2 October 2023.

ENQUIRIES:

Bridgepoint

Analysts and investors	Media
Adam Key	Christian Jones / James Murray
adam.key@bridgepoint.eu	christian.jones@bridgepoint.eu
+44 7833 748010	james.murray@bridgepoint.eu
	+44 20 7034 3500

FGS Global (Public Relations Adviser to Bridgepoint)

James Murgatroyd / +44 20 7251 3801 / +44 7768 254 911 Anjali Unnikrishnan / +44 20 7251 3801 / +44 7826 534 233 Anna Tabor / +44 20 7251 3801 / +44 7584 593 926 bridgepoint-LON@fgsglobal.com

Legal Entity Identifier (LEI): 213800KFNMVI8PDZX472

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

IOEBGBDGCBGDGSB